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REVIEW
Drug Dosing in Pregnant Women: Challenges and
Opportunities in Using Physiologically Based
Pharmacokinetic Modeling and Simulations
Alice Ban Ke1*, Rick Greupink2 and Khaled Abduljalil1
The unmet medical need of providing evidence-based pharmacotherapy for pregnant women is recognized by the regulatory
bodies. Physiologically based pharmacokinetic (PBPK) modeling offers an attractive platform to quantify anticipated changes
in the pharmacokinetics (PKs) of drugs during pregnancy. Recent publications applying a pregnancy PBPK module to the
prediction of maternal and fetal exposure of drugs are summarized. Future opportunities to use PBPK models to predict
breast milk exposure and assess human fetotoxicity risks are presented.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 103–110; doi:10.1002/psp4.12274; published online 19 January 2018.
CURRENT STATUS AND NEED FOR CLINICAL
STUDIES IN PREGNANT WOMEN
The treatment of medical conditions during pregnancy is
often necessary, whether to improve the mothers’ quality of
life or to treat diseases that threaten their health, the fetus’
normal development, or the lives of both.1 Pregnant women
and their fetuses are orphan populations with respect to the
safety and efficacy of drugs. In the United States, over 89%
of women use at least one prescription or over-the-counter
medication during pregnancy,2 despite the fact that 70% of
the medications approved in the United States between
2000 and 2010 have no human pregnancy data and 98%
have insufficient published data to determine the terato-
genic risk in humans.3 At a multinational level across
Europe, North and South America, and Australia, a cross-
sectional, web-based survey4 found that 81.2% of pregnant
women reported the use of at least one medication. Almost
70% of the women reported the treatment of an acute or
short-term illness and 17% reported treatments for chronic
or long-term illnesses. Overall, the most frequently used
medications in pregnancy, either prescription or over-the-
counter, were taken to treat acute conditions that may be
exacerbated by pregnancy, such as headaches, general
aches and pain, gastric reflux, cold symptoms, nausea, and
urinary tract infections. The most common chronic condi-
tions for which medications were administered include
allergy, asthma, thyroid conditions, and depression, or
pregnancy-related conditions, such as gestational diabetes
and hypertension.4 The treatment of pre-existing or self-
limiting chronic conditions including viral (e.g., human
immunodeficiency virus (HIV)), fungal, or bacterial infec-
tions, solid organ transplantation, smoking cessation, and
epilepsy are also common.
Pregnant women are rarely included in clinical trials for
numerous practical, legal, and ethical reasons. Most drugs
are prescribed to pregnant women off-label; the dose
administered is usually based on the recommended dose
for men or nonpregnant women combined with the clini-
cian’s judgment. One case in point is the pharmacotherapy
of pregnant HIV-infected women. Prescribing pregnant HIV-
infected women with combination antiretroviral treatment is
critical for the prevention of mother-to-child transmission of
the virus, and adequate maternal exposure to antiretroviral
drugs is required for the maximal reduction of viral load
and the reduced risk of viral transmission. Reductions in
maternal exposure to these drugs during pregnancy may
lead to subtherapeutic levels, as shown for a number of
drugs, including atazanavir, indinavir, ritonavir, darunavir,
and efavirenz,5–8 eventually leading to virologic failure and/or
drug resistance. Historically, for several antiviral drugs (e.g.,
tenofovir, darunavir, and efavirenz) there has been a signifi-
cant lag time, ranging from 8–15 years between the initial US
Food and Drug Administration (FDA) approval of a drug and
the time when pregnancy data first became available
(personal communications with Drs Stein Schalkwijk and
Angela Colbers, Radboud University Medical Center, Nijmegen,
The Netherlands). Alternative, mechanism-driven approaches
for designing appropriate dosing regimens, and, importantly,
to shorten the lag time for newer treatment options (e.g.,
dolutegravir, elvitegravir, and cobicistat) are highly desirable.
This review highlights a case example that demonstrates
the utility of physiologically based pharmacokinetic (PBPK)
model predictions in selecting the most optimal dose for dar-
unavir/ritonavir, taking into account both maternal and fetal
drug exposure.9,10
The intentional or unintentional maternal exposure to
drugs in early pregnancy is often accompanied by concerns
regarding potential teratogenic effects, as illustrated by the
well-known case of thalidomide in the mid-20th century.
Fetal drug exposure in later trimesters may also lead to
complications, as drugs may interfere with fetal growth or
result in the acute interference of key homeostatic pro-
cesses in the unborn child. Examples include intra-uterine
exposure to opioid analgesics, resulting in postpartum
withdrawal symptoms and respiratory depression in the
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newborn.11,12 There are also cases in which maternal drug
treatment is prescribed to treat or prevent disease in the
unborn child. Challenging examples of the latter are the
titration of the mother with anti-arrhythmic agents to reach
an adequate fetal drug exposure to treat fetal cardiac
arrhythmia13 and the maternal treatment with antiretroviral
agents to prevent maternal-to-child-transmission of the HIV
virus at the time of delivery.14
The FDA also recognizes that clinicians need more infor-
mation to make appropriate dosing decisions for their preg-
nant patients. The FDA’s Pregnancy and Lactation Labeling
Rule (PLLR), which took effect on 30 June 2015, requires
that all prescription drug and biological products remove
the pregnancy letter categories A, B, C, D, and X from their
product labeling over the next 2–4 years.15 The PLLR rule
further specifies that in Section “8.1 Pregnancy” the drug’s
labeling “must also contain relevant information, if it is avail-
able, to help health care providers make prescribing deci-
sions and counsel women about the use of the drug during
pregnancy; this could include information on disease-
associated maternal and/or embryo/fetal risk, dose adjust-
ments during pregnancy and the postpartum period,
maternal and fetal/neonatal adverse reactions, etc.” The
PLLR rule, defined above, should also be applied to Sec-
tion “8.2 Lactation,” which is intended to provide information
about using the drug while breastfeeding, including the
amount of drug present in breast milk and the potential
effects on the breastfed infant. In the absence of pharmaco-
kinetic (PK) data from clinical pregnancy and lactation stud-
ies, alternative approaches, such as PBPK modeling and
simulation, may inform this additional dosing information.
PHYSIOLOGICAL CHANGES DURING PREGNANCY
Pregnancy is associated with a multitude of temporal physi-
ological and metabolic changes,16 and these changes in
maternal physiology can have a direct effect on drug
absorption, distribution, metabolism, and excretion (ADME).
Various pregnancy-related hemodynamic changes lead to
an increase in plasma volume (up to 50%) and a decrease
in plasma protein binding, which can both alter the appar-
ent volume of distribution of drugs. Serum albumin and
alpha 1 acid glycoprotein concentrations decrease by up to
31% and 19% during late pregnancy, respectively.17 There
is a marked 33% increase in cardiac output during preg-
nancy. The change in maternal hepatic enzyme activity is
cytochrome P450 (CYP) isoform-specific. For example, the
metabolism of drugs catalyzed by selective CYP isoen-
zymes (e.g., CYP3A4, CYP2D6, and CYP2C9) and uridine
diphosphate glucuronosyltransferase (UGT) isoenzymes
(e.g., UGT1A4 and UGT1A1) is increased during pregnancy.
In contrast, CYP1A2 and CYP2C19 activity is decreased dur-
ing pregnancy.16 The magnitude of pregnancy-related induc-
tion in drug-metabolizing enzyme activities can be as high as
300%, as suggested by a study of the kinetics of lamotrigine,
a substrate drug of UGT1A4.18 The causative mechanisms
of hepatic CYP activity changes are believed to be regulated
by rising concentrations of various hormones (e.g., estradiol,
progesterone, or growth hormones).19 The renal excretion of
unchanged drugs is increased during pregnancy owing to an
increase in the glomerular filtration rate and also possibly to
an increase in renal secretion via transporters. Currently,
there is evidence relating to the pregnancy effect on renal
transporter organic cation transporter (OCT) and intestinal/
renal transporter P-glycoprotein, based on metformin20
and digoxin data.21 Future studies should address other
important renal and hepatic transporters, such as organic
anion transporters (OAT) and organic anion-transporting
polypeptides (OATPs) 1B1 and 1B3.
PBPK MODELING AND SIMULATION
PBPK modeling and simulation offers a viable alternative to
clinical trials for this vulnerable patient population. Regula-
tory agencies, such as the FDA and the European Medi-
cines Agency, have adopted PBPK modeling and simulation
to facilitate the review of Investigational New Drug and
New Drug Application submissions to address a variety
of clinical issues, including the assessment of the effect
of intrinsic or extrinsic factors on drug PKs.22–24 In these
applications, PBPK modeling is primarily used to facilitate
the decision making process on whether, when, and how to
conduct a clinical pharmacology study, and, more importantly,
to inform drug labeling to support dosing recommendations.25
Increasingly, the regulatory incentives and challenges in
conducting and obtaining clinical data in special populations
have significantly contributed to the increased use of PBPK
models in pediatric and organ impairment populations.23,26
Under the overarching umbrella of systems pharmacol-
ogy, PBPK models map drug movements in the body to a
physiologically realistic compartmental structure using sets
of differential equations.25 This approach has the advan-
tage of integrating both physiological parameters (e.g.,
time-varying changes in maternal weight, individual organ
volumes/blood flows, cardiac output, glomerular filtration
rate, and drug-metabolizing enzyme activities) that are
important for ADME processes and drug-specific parame-
ters (e.g., physicochemical and in vitro metabolism/
transport characteristics). A number of pregnancy PBPK
models have been reported for pregnant animals and
humans in the past 3 decades, which have mainly been
applied in the risk assessment of environmental chemi-
cals.27,28 Although many of the existing models have con-
sidered parameters, such as developmental change of
distribution volume, blood flow rate in the maternal body,
and the growth of the placental-fetal unit on disposition of
environmental chemicals, few have modeled the absorption,
metabolism, and elimination of drugs.
In 2013, the Simcyp Population-based Simulator offered
the first pregnancy module designed to model the kinetics
of drugs by incorporating time-varying physiology of the vir-
tual population.17,29,30 More recently, other software pro-
viders have started to offer a pregnancy module.31,32 Since
then, a number of publications have provided independent
verification and application of a pregnancy module to study
drugs in the pregnant population. The tested drugs covered
a wide spectrum of clearance mechanisms, including sev-
eral major isoforms of CYP enzymes (CYP3A4, 2D6, 1A2,
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2B6, 2C9, and 2C19),9,33,34 and renal clearance.34,35 These
examples followed the best practice approach in PBPK
modeling of drug PKs in special populations, demonstrating
the performance of drug models for the nonpregnant sub-
jects, verifying the key model components using indepen-
dent clinical PK and drug-drug interaction data, before
predicting the drug PKs in the pregnant subjects (Figure 1).
Justifications on the model assumptions of inclusion of
pregnancy-induced changes that are relevant to major
ADME processes of the test drug were provided. These
model application examples not only helped us gain confi-
dence in the predictive performance of the respective model
components, but also provided information relating to less-
established pregnancy effects on physiology, such as the
effect of pregnancy on drug transporter activities.
For example, CYP3A activity is induced by up to 99%
during the third trimester, as informed by a midazolam PK
study.21 One study36 explored whether a previously devel-
oped PBPK model29 could quantitatively predict PK profiles
of CYP3A-metabolized drugs during the third trimester, and
discern the site of CYP3A induction (i.e., liver, intestine, or
both). The PBPK model successfully predicted midazolam,
nifedipine, and indinavir disposition during the third trimes-
ter. A sensitivity analysis suggested that CYP3A induction
in the third trimester is most likely hepatic and not intesti-
nal. CYP1A2 enzyme activity, as measured by caffeine sali-
vary clearance, is suppressed by up to 65% in the third
trimester. A PBPK model incorporating this decrease in
1A2 activity predicted a modest increase (25%) in theophyl-
line exposure during pregnancy, which was consistent with
the observed data.30 For CYP isoforms, such as CYP2B6,
in which PK data obtained from the dosing of a sensitive
probe drug are lacking, an in vitro to in vivo extrapolation
(IVIVE) approach was utilized to predict the pregnancy-
related induction effect from in vitro human hepatocyte
incubations with clinically relevant concentrations of estra-
diol. A PBPK model accounting for a CYP2B6 induction of
up to 90% as well as known pregnancy effects on other
clearance pathways, including CYP3A, CYP2C19, and
renal clearance, successfully predicted methadone disposi-
tion during the second trimester and the third trimester as
compared with the observed data.33 Additional performance
verification utilizing efavirenz data7 would be helpful to fur-
ther verify the pregnancy-induced effect on CYP2B6.
PBPK modeling of renally excreted antiretroviral drugs,
including tenofovir, emtricitabine, and lamivudine in pregnant
women, have shown that the maximum clearance increases
were 30%, which are in agreement with the observed
data.35 Importantly, the authors showed that for all three
drugs, both renal filtration and renal secretion of drugs
increased during pregnancy, the latter being approximated
by pregnancy-induced changes in renal plasma flow. Tenofo-
vir is mainly a substrate for OAT1, whereas emtricitabine and
lamivudine are both substrates for OCT2. Additional sensitiv-
ity analysis results suggest that there seems to be insignifi-
cant changes in renal transporter activity during pregnancy,
including OCT2 and OAT1, or alternatively, the kinetics of
these three drugs were not sensitive markers for the respec-
tive renal transporters likely due to a more significant secre-
tion clearance attributable to passive diffusion. In another
study, PBPK modeling of oseltamivir carboxylate, a drug pre-
dominantly eliminated by renal OAT1 and OAT3, in pregnant
women, informed pregnancy-induced changes in OAT.37 The
sensitivity analysis revealed that OAT-mediated renal clear-
ance for oseltamivir carboxylate needed to be increased by
100% to recover oseltamivir carboxylate PK during preg-
nancy. One can explore PK changes of other OAT-substrate
drugs (e.g., ciprofloxacin) in pregnant women.38
Figure 1 The best practice approach to physiologically based pharmacokinetic (PBPK) model development and application in pregnant
women. ADME, absorption, distribution, metabolism, and excretion; DDI, drug-to-drug interaction; PK, pharmacokinetic.
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Despite these aforementioned successes in the applica-
tion of PBPK modeling in the pregnant population, several
challenges still exist. First, although there is adequate litera-
ture evidence documenting the key physiological, biochemi-
cal, and metabolic changes occurring during pregnancy, the
granularity of information (e.g., the gestation age-dependent
changes especially during early gestation) and the impact on
the overall PK outcome has not always been sufficiently veri-
fied to warrant incorporating all these changes in the
model.27 For example, the changes in hepatic enzyme activ-
ity are typically informed by probe-drug studies. For the
majority of the probe-drug studies conducted in pregnant
women, data are obtained only in the third trimester as some
probe drugs cannot be safely administered to pregnant
women during early gestation if they are not used for thera-
peutic purposes. Opportunistic PK studies in pregnant
women are also likely restricted to the phase of pregnancy
during which the patients are afflicted with the disease. In
any case, extrapolating the magnitude of change in CYP
enzyme activity from one trimester to other trimesters may
be difficult. Similar issues also need to be addressed for
several intestinal, renal, and hepatic transporters such as
P-glycoprotein (P-gp), OATP1B1/3, OCT2, and OAT1/3. Sec-
ond, the system data used to populate the current pregnancy
PBPK models mainly came from healthy pregnant women
with singleton births,17 and, as a result, the potential effects
on drug PKs due to concomitant diseases are not consid-
ered. Finally, an added complexity is that there are potential
pharmacodynamic (PD) changes during pregnancy, such as
a higher degree of insulin resistance exhibited by the women
with gestational diabetes, and immunosuppression during
pregnancy that may impact the PD response to antibiotics.39
Because the efficacy of drugs will be influenced by alteration
in the PK and the PD of drugs, the latter, when and if readily
quantified, should be included as another component to
guide dose adjustment in pregnancy.
DARUNAVIR/RITONAVIR CASE EXAMPLE
Recently, Colbers et al.9 used PBPK modeling to delineate
the potential impact of drug transporters on darunavir PK
and to identify current knowledge gaps that limit the accu-
rate prediction of darunavir/ritonavir exposure in pregnancy.
In addition, PBPK modeling was used to quantitatively
assess the impact of drug-drug interactions. For example,
ritonavir, a strong CYP3A4 inhibitor, is used as a booster to
intentionally increase the exposure of antiretroviral drugs
that are metabolized by CYP3A4, including darunavir. Ini-
tially, the authors used a well-stirred liver model incorporat-
ing the Michaelis-Menten constant (Km) and the maximum
rate of metabolite formation (Vmax) for CYP3A4-mediated
darunavir metabolism, and the simulations overestimated
the total exposure of darunavir when compared with the
clinical data. These results indicate the involvement of
active transport in the hepatic disposition of darunavir. In
the absence of definitive transport data, the authors derived
a hepatic uptake component and an efflux component using
sensitivity analysis. Subsequently, simulations using a
permeability-limited liver model, including hepatic uptake
mediated by OATPs and efflux mediated by P-gp followed
by enterohepatic circulation resulted in an acceptable
recovery of darunavir/ritonavir exposure. The ritonavir
model incorporated in vitro CYP3A4 inactivation parameters,
as well as competitive inhibition constants for hepatic
OATP2B1 and P-gp. For the dosing regimens of 600/100 mg
darunavir/ritonavir twice daily (b.i.d.) and 800/100 mg once
daily (q.d.), the predicted PK parameters were within a two-
fold range of the observed data in the nonpregnant subjects.
For the pregnant subjects, the predicted decreases in the
area under the curve (AUC) values during pregnancy for the
b.i.d. and q.d. regimens were 27% and 41%, respectively,
consistent with the observed decreases of 17–22% and
33%. These results informed the selection of alternative dos-
ages (800/100 mg b.i.d. and 900/100 mg b.i.d.) that are being
investigated in clinics, the outcome of which will allow further
verification of the model. This case example nicely illustrates
the utility of PBPK model predictions in choosing the most
optimal dose in a complex case, when the disposition of the
drug is determined by the interplay of hepatic uptake/efflux
transporters and hepatic CYP3A4, the combined inhibitory
effects from ritonavir, as well as the pregnancy effects on all
these processes.
MODELING PLACENTAL TRANSFER AND FETAL
EXPOSURE OF DRUGS
Understanding the relationship between external dose and
fetal exposure of drugs is a key step in understanding
potential harmful or beneficial effects of maternal drug
treatment for the unborn child. Although the extent and rate
of placental drug transfer is highly dependent upon the
physicochemical properties of the drug,40 this also varies
considerably between species.41 The latter reflects the sig-
nificant variation in placental anatomy and hemodynamics
between human and different animals. In addition, potential
differences in the expression of placental drug transporters
and drug metabolizing enzymes, as well as their substrate
specificities, can contribute to this phenomenon. Hence,
PBPK modeling, based on IVIVE approaches of data obtained
with human tissues and cells, is a relevant approach for pre-
dicting the rate and extent of the placental transfer of drugs in
pregnant women.
PBPK models that adequately describe the placental
transfer of drugs should ideally include a description of the
gestational changes in maternal physiology that impact
drug disposition, incorporate changes that occur in placen-
tal physiology, as well as include a description of changes
in fetal drug disposition and clearance over time. Zhang
et al.42 described such a feto-pregnancy-PBPK model in
which a placenta, amniotic fluid compartment, and fetal
organs that are relevant to drug disposition were added,
the model also took into account typical characteristics of
the fetal circulation. Gestational age-dependent changes in
fetal, placental, and maternal physiological parameters dur-
ing the second half of pregnancy were described using
empirically derived polynomial equations.42 Using the
model, the authors elegantly demonstrated that cord to
maternal plasma ratios, even at distribution equilibrium, do
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not indicate fetal drug exposure relative to that in the
mother, which is due to the time-dependent distributional
kinetics of drugs across the placenta. In addition, they used
sensitivity analysis to assess the possible impact of gesta-
tional age-dependent changes in placental metabolism and
transport processes on placental transfer. To verify perfor-
mance of the model for predicting the placental passage of
only passively diffusing drugs, the authors populated the
model using midazolam as a calibrator drug, and subse-
quently verified the model by adequately predicting the fetal
exposure of two other passively diffusing drugs, theophyl-
line and zidovudine.42 For antiretroviral agents, similar
approaches for incorporating placental transfer and drug
disposition in lumped fetal compartments have been
described by De Sousa Mendes et al.43 and Schalkwijk
et al.10 These authors use ex vivo placenta perfusion data
obtained from term human placentas in a bottom-up
approach to parameterize the placental passage model
parameters with clearance values or rate constants for
maternal to fetal transfer and vice versa. In these reports,
the predictions of fetal exposure at term were also success-
fully verified against clinical drug levels measured in cord
blood samples.
Specifically, Schalkwijk et al.10 conducted a follow-up
investigation of the darunavir study by Colbers et al.6,9 with
the aim of incorporating placental transfer into the estab-
lished pregnancy PBPK model of darunavir to simulate fetal
darunavir exposure at term. The authors determined
maternal-to-fetal and fetal-to-maternal darunavir/ritonavir
placental clearance with an ex vivo human cotyledon perfu-
sion model. These placental transfer clearance values were
then used to link a feto-placental unit to the maternal PBPK
model. For model qualification, simulated maternal and fetal
PK profiles were compared with clinical data obtained dur-
ing the third trimester and at the time of delivery. The veri-
fied model was then used to simulate fetal PK profiles at
different maternal darunavir/ritonavir dosing regimens. For
darunavir 600/100 mg b.i.d., the predicted fetal maximum
plasma concentration, trough concentration, time to maxi-
mum plasma concentration, and half-life were 1.1, 0.57 mg/
L, 3, and 21 hours, respectively. Because the predicted
fetal trough concentration is higher or around the half-
maximal effective darunavir concentration for a resistant
virus (0.55 mg/L), these results support the theory that the
fetal exposure after oral maternal darunavir given at the
standard dosages is therapeutic.
The advantage of using ex vivo placental perfusion data
for model parameterization is that the data intrinsically cap-
tures both passive as well as active transfer processes acting
on the drug.44–46 Despite these promising results, prediction
of fetal exposure at earlier gestational ages is still difficult. To
allow the prediction of the placental transfer of drugs, mecha-
nistic PK data on these placental processes also needs to be
established, but generating data via ex vivo placenta perfu-
sion at earlier gestational ages is technically challenging and
not very well established.47 An alternative approach could be
to generate in vitro kinetic parameters (Km, Vmax, or intrinsic
clearance values) of drugs in recombinant transporter and
drug metabolizing enzyme overexpression systems, as well
as passive permeability via in vitro measurements in cellular
monolayers. For successful IVIVE of placental clearance
from these in vitro kinetic parameters, further knowledge of
the abundance of specific placental enzymes and the abun-
dance of transporters in the membranes of placental syncy-
tiotrophoblasts and fetal capillary endothelial cells is
required. To move this approach forward, the measurement
of gestational age-dependent changes in the expression lev-
els of placental enzymes is required to parameterize feto-
pregnancy-PBPK models accordingly. Finally, it is important
that sufficient and high quality clinical data for validation pur-
poses becomes available. In particular, this includes the well-
timed collection of cord and maternal blood samples, as was
also noted by others, but we would like to stress that this
should include gathering clinical data on placental drug con-
centrations as well.
MODELING BREAST MILK EXPOSURE OF DRUG
In response to the PLLR rule calling for prescribing informa-
tion on the predicted amount of drug appearing in breastmilk,
Abduljalil et al.48 developed a dynamic lactation model con-
sisting of three compartments, mammary blood, the tissue
itself, and the milk. The model incorporates physiological
parameters, including the tissue volume and blood flow, milk
pH, and the milk intake, along with individual physiological
parameters and their variability. The model was integrated
within the Simcyp Simulator using a first order absorption
model and the Rodgers & Rowland49 method to predict the
partition of drugs between tissues and plasma. In addition,
the elimination kinetics of administered drugs were predicted
using IVIVE. The kinetics of single-dose alprazolam (0.5 mg)
and caffeine (200 mg) were predicted and the outcomes
were compared with the reported data. The model prediction
of milk and plasma AUC0–24h values were within twofold of
the observations. In another application, the lactation PBPK
model was used to predict the concentration of tramadol in
breastfeeding mothers who are extensive metabolizers of
CYP2D6.50 The results were in agreement with the clinical
observations. The model was then used to predict tramadol
concentration in the plasma and milk for poor and ultrarapid
metabolizer subpopulations. The infant daily doses were cal-
culated after maternal intake of the drug. These encouraging
results demonstrated that the three-compartmental model for
mammary gland coupled with the PBPK model is useful to
explore scenarios in which clinical observations are not avail-
able to predict the amount of drug ingested by the neonate.
Although the disposition of these compounds is mainly
governed by passive permeability, future work will focus
on extending the model to predict the concentration and
distribution of compounds whose kinetics involve drug
transporters.
FUTURE OPPORTUNITIES – A MECHANISTIC
FRAMEWORK FOR PREDICTING HUMAN
FETOTOXICITY RISK
We believe that with the established base of knowledge
relating to the profound physiological changes during
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pregnancy and the significant advances in PBPK approaches
that have been applied in special populations (such as pedi-
atric populations), the PBPK approach during pregnancy
offers an attractive tool to quantify anticipated changes in the
PK of drugs during pregnancy. Conducting trials in silico
before executing them in vivo can also be helpful in optimiz-
ing the design of a first-in-pregnancy PK study, including the
prioritization of the study period, the sample size, and the
dose selection.
The coupled maternal-fetal physiology imposes additional
concerns about both efficacy and safety of treatment. To
assess fetal exposure to drugs administered to the mother,
the established maternal PBPK model has recently been
expanded to include a fully physiological fetal model to
allow the quantitative predictions of fetal systemic and tis-
sue exposures.51 This is the first step toward providing a
mechanistic framework for applying a PBPK feto-maternal
model to predict human fetotoxicity risk from preclinical
species (Figure 2). In contrast with existing PBPK feto-
maternal models in the literature in which many of the lon-
gitudinal changes of physiological parameters were largely
based on scaling rat data, the model by Abduljalil et al.51 in
2017, was fully parameterized with human physiology data
with respect to tissue growth, blood flow, binding proteins,
and drug metabolizing enzymes together with the associ-
ated variability with these parameters, which are necessary
in order to broaden its application particularly in drug dis-
covery and development for pregnant women. For example,
the PBPK platform can provide a means to estimate thera-
peutic concentrations of drugs (e.g., antiretrovirals or antiar-
rhythmics treating in utero conditions of the fetus).
Animal models remain an important source of information
on maternal-fetal toxicity. However, the specific types of
developmental effects caused by xenobiotics may vary
widely between animal models and humans due to biologi-
cal differences, and this can pose a problem in translating
the toxicological observations from animals to humans.
Application of the PBPK feto-maternal model can comple-
ment the traditional fetotoxicity studies in preclinical animals
to identify the toxic doses that can cause feto-toxic drug
levels after accounting for species differences in physiologi-
cal and biochemical parameters. The human PBPK model
that predicts the systemic exposure in the fetus and mother
can be used to simulate the local fetal tissue concentration,
the latter can be linked to the predicted toxicity after
accounting for any potential species differences in the
Figure 2 A mechanistic framework for applying a physiologically based pharmacokinetic (PBPK) feto-maternal model for predicting
human fetotoxicity risk from preclinical species described in the following steps. (1) Perform fetotoxicity studies in preclinical animals
and establish exposure-toxicity relationships. (2) Construct a coupled feto-maternal PBPK model that accounts for gestational age
related changes in the physiology and placenta to describe the relationship between fetal tissue and systemic concentrations together
with maternal systemic concentration. (3) Use the constructed PBPK model to find the toxic doses that can cause feto-toxic drug levels
after accounting for species differences in physiological/biochemical parameters (number of placentas, weight, blood flow, transporters,
and enzyme expression). (4) The human PBPK model can also be refined if in vitro and/or in vivo human data are available. (5) The
human PBPK model that predicts the systemic exposure in fetus and mother can be used to predict the local fetal tissue concentration.
(6) Fetal local tissue concentration can be linked to the predicted toxicity after accounting for any potential species differences in the
toxicodynamic model. This figure is adapted from the publication by Abduljalil et al.51 Conc, concentration; IC50, half-maximal inhibitory
concentration.
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toxicodynamic model. This approach now has special rele-
vance in relation to recent FDA regulatory guidance on
drugs in pregnancy and lactation,15 which emphasized the
need to distinguish between risks based on human vs.
animal data findings or between differences in frequency,
severity, and type of fetal developmental toxicities. We
believe that PBPK feto-maternal models will be highly desir-
able to support fetal exposure assessment. Once verified,
these models have the potential to better translate risk
assessment in animals to human scenarios, and to help
elucidate appropriate dosing information for pregnant
women and their unborn children.
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